Health 20 February 2026 - 10 March 2026

DiaMedica Shares Down Ahead of Stroke Trial Update
····

DiaMedica Shares Down Ahead of Stroke Trial Update

DiaMedica Therapeutics Inc. shares fell Tuesday, with the drug developer closing lower as the major indexes gained. The stock was last at $5.77 after hours, off 6 cents from its close. It traded between $6.29 and $5.56 earlier in the session. Volume reached about 152,000 shares. Market cap was roughly $311 million. DiaMedica is heading into a catalyst week as it prepares to present at 3:45 p.m. ET Thursday during the Jefferies Global Healthcare Conference in New York. The event, which runs June 2-4, draws attention from healthcare investors looking for pipeline news and signs of financing.
June 2, 2026
Hims & Hers Health Stock Jumps Again as Novo Nordisk Deal Ends Wegovy Fight
···

Hims & Hers Health Stock Jumps Again as Novo Nordisk Deal Ends Wegovy Fight

Hims & Hers Health climbed for a second day on Tuesday, with shares up roughly 11% at $24.70 in early trading, after Novo Nordisk agreed to make Wegovy and Ozempic available via the telehealth company’s platform. That deal also put an end to a recent patent dispute between the two. The stock had already surged over 40% on Monday. This is significant for Hims, removing a legal and regulatory cloud from its weight-loss operations. The dispute involved compounded GLP-1 drugs—tailor-made alternatives to well-known diabetes and obesity meds—right as the company flagged a $65 million hit in the first quarter and set guidance below what analysts were looking for.
March 10, 2026
Haleon PLC’s Centrum Silver May Slow Biological Aging, Nature Medicine Study Finds
···

Haleon PLC’s Centrum Silver May Slow Biological Aging, Nature Medicine Study Finds

Haleon’s Centrum Silver multivitamin showed a slight slowdown in biological aging markers among older adults, according to an ancillary analysis from the COSMOS trial, detailed in a Nature Medicine paper published Monday. The findings land as a scientific boost for the British consumer health group’s flagship brand. Timing counts for Haleon. Back on Feb. 25, the company set its sights on 2026 organic revenue growth between 3% and 5% — that’s excluding currency effects and recent acquisitions — after soft U.S. demand and aggressive price moves from competitors took a bite out of sales. “The squeeze is apparent even in over-the-counter medicines,” noted Chris Beckett at Quilter Cheviot.
March 9, 2026
Banco Bradesco Moves Bradsaúde Plan Ahead as Odontoprev Sets April Vote
···

Banco Bradesco Moves Bradsaúde Plan Ahead as Odontoprev Sets April Vote

Banco Bradesco faces two shareholder votes later this month, following a filing that confirmed its healthcare restructuring is still moving forward. Odontoprev has scheduled an April 6 meeting for the next step in the process. According to the bank, the latest documents leave the deal's terms unchanged. The schedule is tight: Bradesco shareholders have a March 31 vote on a partial Bradseg spin-off—essentially, a carve-out from the unit. Over at Odontoprev, investors decide April 6 on authorizing new shares to take in Bradesco Gestão de Saúde, boosting capital, and switching the name to Bradsaúde. That would put Odontoprev at the center as the group’s top-listed healthcare arm.
March 9, 2026
Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing
···

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing

Xenon Pharmaceuticals Inc reported Monday that its experimental epilepsy drug azetukalner reduced monthly focal onset seizures in a late-stage study, sparking a jump of over 40% in the stock before the bell. William Blair’s Myles Minter, in a note to clients, described the results as “unprecedented.” Xenon is feeling the heat as it waits to see if azetukalner can deliver enough for an approval push this year. That window is now off the table: the company says it’s aiming to file its New Drug Application in the third quarter of 2026.
March 9, 2026
Moderna’s $2.25 billion patent settlement clears a major cloud over its COVID vaccine tech
···

Moderna’s $2.25 billion patent settlement clears a major cloud over its COVID vaccine tech

Moderna has agreed to settle its patent dispute with Arbutus Biopharma and Genevant Sciences, putting an end to litigation over mRNA vaccine technology. The company will pay $950 million during the third quarter of 2026—no ongoing royalties attached. With a Delaware jury trial looming, Moderna has struck a deal that removes a major legal overhang as it works to stabilize its balance sheet amid declining COVID vaccine sales. Evercore ISI analysts described the timing as “down to the wire,” noting the settlement wipes out what they called a “meaningful tail risk.”
March 5, 2026
Unilever PLC’s India unit closes 3.07 billion-rupee Nutritionalab exit in wellness reshuffle
···

Unilever PLC’s India unit closes 3.07 billion-rupee Nutritionalab exit in wellness reshuffle

Hindustan Unilever, the Indian arm of Unilever PLC, has wrapped up the sale of its entire stake in Nutritionalab Private Limited, pocketing roughly 3.07 billion Indian rupees, a stock exchange filing dated March 4 shows. The company offloaded its whole 19.8% interest, with the disclosure made under India’s “Regulation 30” rules — a requirement for listed companies to report any material developments. This isn’t a transformative move for the group by itself. What’s at stake: Unilever remains under pressure to show that zeroing in on higher-margin segments can deliver, even as demand wobbles—particularly in major emerging economies.
March 5, 2026
Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns
···

Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns

New York, March 3, 2026, 13:41 ET — Regular trading hours Amgen Inc shares dropped $8.69, or 2.3%, to $377.01 as of 1:41 p.m. ET Tuesday, after Kyowa Kirin out of Japan pulled the plug on all current trials for its experimental drug rocatinlimab. The Japanese company had previously wrapped up its development and commercialization partnership with Amgen around rocatinlimab.
March 3, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

NEW YORK, Feb 20, 2026, 16:53 EST — After-hours Grail plunged roughly 50% to $50.21 after hours on Friday, following news that its key UK trial for the Galleri cancer blood test failed to hit the main endpoint. TD Cowen’s Dan Brennan said Grail should address the mixed results with “proactive, transparent and deliberate” communication about the next steps.
February 20, 2026
1 2 3 4 5 6